Skip to Main

Placement Agent on Skye Bioscience's $50MM Private Placement Financing

  • Oppenheimer & Co. Inc.
  • February 9, 2024
Oppenheimer &. Co. Inc. acted as Placement Agent on Skye Bioscience’s $50MM Private Placement Financing

Skye Bioscience, Inc. (the “Company”) (OTCQB: SKYE), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, announced that it entered into a securities purchase agreement for the sale of (i) 11,713,664 shares of its common stock at $2.305 per share and (ii) to certain investors, in lieu of common stock, pre-funded warrants to purchase up to 9,978,739 shares of common stock at a price of $2.3049 per pre-funded warrant in a private placement (the “PIPE”) to certain qualified institutional buyers. The pre-funded warrants will have an exercise price of $0.001 per share, will be exercisable immediately and will be exercisable until exercised in full. Gross proceeds from the PIPE amounted to $50 million.

insights report
insights report

The PIPE financing was co-led by a life sciences-focused investor and existing investor 5AM Ventures, with participation from Ally Bridge Group, Sphera Healthcare, Altium Capital, Driehaus Capital Management and other institutional investors. The Company expects the PIPE financing net proceeds to fund its operations into early 2026 through a set of key milestones and operations encompassing: a Phase 2 clinical trial for nimacimab in obesity; a Phase 2a clinical trial for SBI-100 Ophthalmic Emulsion (“OE”) in glaucoma and ocular hypertension; and a Phase 2b trial of SBI-100 OE for glaucoma and ocular hypertension.

Michael Margolis

Michael A. Margolis, R.Ph.


Senior Managing Director, Co-Head of Healthcare, Head of Healthcare Life Sciences

Name: Title:


This notice is provided for informational purposes only, and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.

This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.

2023 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC 6381187.1